1179031-47-0

Usage

Uses

Used in Pharmaceutical Industry:
N-(2-chloroallyl)-2,3-dihydro-1H-inden-1-amine is used as an active pharmaceutical ingredient for the treatment of Parkinson's disease. As Rasagiline (R126030), it functions by increasing the availability of dopamine at striatal receptors, which helps alleviate the motor symptoms associated with the disease. Its selective and potent action on monoamine oxidase B (MAO-B) enzyme contributes to its therapeutic efficacy, making it a valuable drug for managing the progressive neurodegenerative disorder.

Upstream product

• 1875-50-9 N-propargyl-1-aminoindan 

Relevant academic research and scientific papers

Synthesis and characterization of impurities in rasagiline: A novel MAO-B inhibitor in Parkinson's disease therapy

Rasagiline (1) is indicated as adjunctive therapy and monotherapy for treatment of Parkinson's disease approved by the FDA. During the process development of rasagiline, few processes related impurities were observed along with the final API. These impurities were identified as indanol (2), indanamine (3), allyl (4), keto (7), other isomer (6) and chloro allyl (5,5a) impurities. The present work describes the synthesis of all these impurities and characterized by 1H NMR and Mass spectral analysis.

A PROCESS FOR THE PREPARATION OF (R)-I -AMINOINDANES

The present invention relates to a process for the preparation of the chiral compound of formula (V), wherein R1 is a C1-C6 alkyl group optionally substituted with halogens, an aryl optionally substituted, or a trialkyl silyl group, for use as an intermediate in the preparation of (R)-1-aminoindanes, helpful in the pharmaceutical field. The compound of formula (V) is a key intermediate to the preparation of (R)-1- aminoindanes, particularly Rasagiline. The invention also relates to novel compounds, which are especially useful as intermediates for the preparation of (R)-1- aminoindanes.